The results provide more justification for the FDA to grant the substance emergency use authorization.
News & Analysis: Grifols
Each company has a triad of COVID-19 projects, but they aren't in direct competition.
Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.
The real question is whether growing product sales can outpace increasing R&D expenses.
Grifols isn't well-known, but it holds over 20% share in a $10 billion-plus market growing more than 6% a year.
These three technology firms lead the way.
Nokia and Grifols give investors some good news, while Arm Holdings rebounds.